These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience.
    Author: Leboulanger N, Fayoux P, Teissier N, Cox A, Van Den Abbeele T, Carrabin L, Couloigner V, Nicollas R, Triglia JM, Ayari S, Froehlich P, Lescanne E, Marianowski R, Mom T, Mondain M, Marie JP, Roger G, Garabédian EN, Denoyelle F.
    Journal: Int J Pediatr Otorhinolaryngol; 2010 Nov; 74(11):1254-7. PubMed ID: 20800295.
    Abstract:
    OBJECTIVE: Preliminary assessment of the efficacy of propranolol on subglottic hemangioma in children on a nation-wide scale. METHODS: Multicentric, retrospective study of clinical files of 14 children; pre- and post-treatment endoscopies. RESULTS: Mean age at diagnosis was 2.3 (0.7-4) months. Mean percentage of airway obstruction was 68% (15-90) before propranolol introduction. Propranolol was started at 5.2 (0.7-16) months of age. This treatment was effective in all cases with a mean regression of the stenosis to 22% after 2 weeks and 12% after 4 weeks. Other medical treatments (steroids) could be stopped. In one patient, a side effect of propranolol motivated the switch to another β-blocker. In four patients, treatment was stopped after 5.2 (1-10) months with a relapse in 2 (50%) cases. One of these two patients developed a resistance to propranolol and required a surgical procedure by external approach. CONCLUSION: This preliminary nation-wide survey confirms propranolol high effectiveness against airways' localization of infantile hemangiomas. Propranolol also allows alleviation or cut-off of previous medical treatments. However, recurrences are possible after early treatment interruption.
    [Abstract] [Full Text] [Related] [New Search]